AI assistant
Cellectar Biosciences, Inc. — Director's Dealing 2024
Jun 18, 2024
35021_dirs_2024-06-18_a23e7498-2ea3-4bcb-9143-a658f964b8f0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2024-06-14
Reporting Person: CARUSO JAMES V (Director, President and CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-14 | Stock option (right to buy) | $2.65 | A | 900000 | Acquired | 2033-12-15 | Common Stock (900000) | Direct |
Footnotes
F1: This option was contingently granted on December 15, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024.
F2: This option shall vest over a period of three years from December 15, 2023, with 1/3 vesting on the first anniversary of Decembner 15, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of Decembner 15, 2023.